News Releases

Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D

Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma

FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma

CStone sells to Servier its exclusive rights to TIBSOVO®in Greater China and Singapore

Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo® Use at ASH 2023